Apica Publishes in European Journal of Cardio-Thoracic Surgery.
5 April 2013 Dublin. Leading International clinicians have published the first paper on the clinical use of Seroba Kernel’s investee company, Apica Cardiovascular’s Access and Closure Device to deliver aortic valves through the apex of the heart. The paper, published in the Journal of Cardio-Thoracic Surgery (April 2013), was titled ‘First-in-man evaluation of the transapical APICA ASC™ access and closure device: the initial 10 patients’ and it was submitted for publication by authors – Johannes Blumenstein, Joerg Kempfert, Arnaud Van Linden, Mani Arsalan, Sina K. Schmidt, Heige Mollman, Won-Keun Kim, Vinod Thourani and Thomas Walther.
The objectives of the study were to evaluate the inital and short term results of a new apical access and closure device to facilitate and standardise the transapical (TA) approach to transcatheter aortic valve implantation (TAVI).
The conclusions were: TA access and closure are both feasible and safe using the APICA ASC™ device. The system facilitates and standardises TA access and closure by providing a sufficient and secure sealing during and after the TAVI procedure.
The paper was initially presented at the 26th Annual Meeting of the European Association for Cardio-Thoracic Surgery, Barcelona, Spain, 27-31 October 2012. It is published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.
For further information, please contact:
Vicky La Touche-Price, Seroba Kernel Life Science, 15 Molesworth Street, Dublin 2. Tel: +3531 6334028.